|本期目录/Table of Contents|

[1]陆明冬,杨川川,吴方丽,等.无载体 RNA纳米颗粒在肝癌细胞 RNAi治疗中的应用[J].浙江理工大学学报,2026,55-56(自科五):670-679.
　LU Mingdong,YANGChuanchuan,WUFangli,et al.Carrier-free RNA nanoparticles for RNAi-based therapy in hepatocellular carcinoma cells[J].Journal of Zhejiang Sci-Tech University,2026,55-56(自科五):670-679.
点击复制

无载体 RNA纳米颗粒在肝癌细胞 RNAi治疗中的应用()

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
55-56
期数:
2026年自科第五期
页码:
670-679
栏目:
出版日期:
2026-09-20

文章信息/Info

Title:
Carrier-free RNA nanoparticles for RNAi-based therapy in hepatocellular carcinoma cells
文章编号:
1673-3851(2026) 09-0670-10
作者:
陆明冬 ; 杨川川 ; 吴方丽 ; 金伟波
1. 浙江理工大学生命科学与医药学院 ,杭州 310018;2. 浙江理工大学绍兴生物医药研究院有限公司 ,浙江绍兴 312366
Author(s):
LU Mingdong; YANGChuanchuan ; WUFangli ; JIN Weibo
1. College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China;2. Zhejiang Sci-Tech University Shaoxing Academy of Biomedicine, Shaoxing312366, China
关键词:
siRNA药物; 人端粒酶逆转录酶; RNA纳米颗粒; 理化性质 ; 肿瘤治疗
分类号:
Q936
文献标志码:
A
摘要:
RNA干扰(RNA interference, RNAi)疗法在遗传病及癌症等疾病治疗中应用潜力巨大 ,但 RNAi递送体系存在稳定性差和潜在毒性等风险 , 限制了其临床应用 。 为提升 RNAi递送效果 , 将靶向人端粒酶逆转录酶 (Human telomerasereversetranscriptase, hTERT)的 4个小干扰 RNA串联 ,使其能自组装形成正方形 ;利用大肠埃希菌制备 hTERT-square纳米颗粒 ,采用动态光散射、透射电镜、实时定量 PCR等技术 ,表征 hTERT-square的理化特征、细胞摄取效率及驻留时长、抗肿瘤效果和 RNAi效率 。结果表明 :hTERT-square的粒径为 50~ 100 nm,具有较高的热稳定性和 RNaseA耐受性;无需额外转染试剂 ,hTERT-square也可进入 Hep3B肝癌细胞 ,驻留时长超过36h,在 24h 内下调 hTERT基因表达约50% ,显著降低 Hep3B细胞的存活率 。该研究可为开发安全、高效的 RNAi抗癌策略提供有力依据。

参考文献/References:

[1] Kim DH, RossiJJ. RNAi mechanismsand applications[J]. BioTechniques, 2008, 44(5) : 613-616.
[2] Setten RL, RossiJJ, HanS P. The current state and future directionsofRNAi -basedtherapeutics[J]. NatureReviewsDrug Discovery, 2019, 18(6) : 421-446.
[3] Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics[J]. Nature Reviews Genetics, 2015, 16(9) : 543-552.
[4] Adams D, Gonzalez-Duarte A, O’ Riordan W D, et al. Patisiran , an RNAi therapeutic, for hereditary transthyretin amyloidosis[J]. The New England JournalofMedicine, 2018, 379(1) : 11-21.
[5] ScottLJ. Givosiran: first approval[J]. Drugs, 2020, 80(3) : 335-339.
[6] HouX, ZaksT, LangerR, etal. LipidnanoparticlesformRNA delivery [J]. Nature Reviews Materials, 2021, 6(12) : 1078- 1094.
[7] KedmiR, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor4 in immune activation[J]. Biomaterials, 2010, 31 (26) : 6867-6875.
[8] Van Der Meel R, Sulheim E, Shi Y, et al. Smart cancer nanomedicine [J]. Nature Nanotechnology, 2019, 14( 11) : 1007-1017.
[9] GearyC, GrossiG, Mcrae E K S, et al. RNA origamidesign tools enable cotranscriptional folding of kilobase-sized nanoscaffolds [J]. NatureChemistry, 2021, 13(6) : 549-558.
[10] YipT, QiX, Yan H, etal. Therapeuticapplications ofRNA nanostructures [J]. RSC Advances, 2024, 14(39) : 28807- 28821.
[11] Zhao M, WangR, YangK, etal. Nucleicacid nanoassembly- enhanced RNA therapeutics and diagnosis [ J ]. Acta PharmaceuticaSinicaB, 2023, 13(3) : 916-941.
[12] AfoninK A, BindewaldE, Yaghoubian A J, et al. In vitro assembly of cubic RNA-based scaffolds designed insilico[J]. NatureNanotechnology, 2010, 5(9) : 676-682.
[13] AfoninK A, Grabow W W , Walker F M, et al. Design and self-assembly of siRNA-functionalized RNA nanoparticles for usein automated nanomedicine[J]. NatureProtocols, 2011, 6 (12) : 2022-2034.
[14] ShayJ W , WrightW E. Role of telomeres and telomerase in cancer [J]. Seminars in Cancer Biology, 2011, 21(6) : 349- 353.
[15] LiuJP. Studiesofthemolecularmechanismsin theregulation oftelomeraseactivity [J]. TheFASEBJournal, 1999, 13(15) : 2091-2104.
[16] ChoiSH, ChoKJ, YunSH, etal. HKR3regulatescellcycle through the inhibition of hTERT in hepatocellular carcinoma celllines[J]. JournalofCancer, 2020, 11(9) : 2442-2452.
[17] HuangFW , HodisE, XuMJ, etal. HighlyrecurrentTERT promotermutations in human melanoma[J]. Science, 2013, 339(6122) : 957-959.

[18] Zhang P  H,  Zou L,  Tu Z G.   RNAi-hTERT  inhibition hepatocellular  carcinoma  cell  proliferation   via  decreasing telomerase activity[J].  Journal of Surgical Research,  2006, 131(1) : 143-149.
[19] GouX, WangW , ZhouF, etal.  siRNA-mediatedinhibitionof hTERT enhanceschemosensitivity ofhepatocellular carcinoma [J].  CancerBiology& Therapy, 2008, 7(10) : 1555-1560.
[20] LiM, Zheng M, Wu S,  et al.  In vivo production of RNA nanostructures via  programmed  folding  of  single-stranded RNAs[J].  NatureCommunications, 2018, 9(1) : 2196.
[21] Shu D,  Shu Y,  Haque F,  et al.  Thermodynamically stable RNA  three-way  junction  for  constructing  multifunctional nanoparticles  for  delivery   of  therapeutics [ J ].     Nature Nanotechnology, 2011, 6(10) : 658-667.
[22] LiH, LeeT, DziublaT, et al.  RNA asa stable polymer to build controllable and defined nanostructures for material and biomedicalapplications[J].  Nano Today, 2015, 10(5) : 631- 655.
[23] TaraporeP, Shu Y, GuoP, etal. Application ofphi29motor pRNA for targeted therapeutic delivery of siRNA  silencing metallothionein-Ⅱ A  and survivin in ovarian  cancers [J]. MolecularTherapy , 2011, 19(2) : 386-394.
[24] BehzadiS, Serpooshan V, Tao W , et al.  Cellular uptake of nanoparticles: journey inside the cell[J].   Chemical Society Reviews, 2017, 46(14) : 4218-4244.
[25] GearyC, RothemundP W K, AndersenES.  A single-stranded architecture    for    cotranscriptional    folding     of    RNA nanostructures[J].  Science, 2014, 345(6198) : 799-804.
[26] AfoninK A, KasprzakW , BindewaldE, etal. Computational and experimental characterization ofRNA cubic nanoscaffolds [J].  Methods, 2014, 67(2) : 256-265.
[27] OnizukaK, HazemiME, ThomasJM, etal. Synthesisofnative- like crosslinked duplex RNA and study of its properties[J]. Bioorganic& MedicinalChemistry, 2017, 25(7) : 2191-2199.
[28] Grabow  W  W ,   Jaeger L.   RNA  self-assembly  and  RNA nanotechnology[J].  AccountsofChemicalResearch, 2014, 47 (6) : 1871-1880.
[29] GuoP.  TheemergingfieldofRNA nanotechnology[J].  Nature Nanotechnology, 2010, 5(12) : 833-842.
[30] Liu J,  Guo S,  Cinier M,  et al.   Fabrication of stable and RNase-resistant RNA  nanoparticles  active in  gearing  the nanomotorsforviralDNA packaging[J].  ACSNano, 2011, 5 (1) : 237-246.
[31] Albanese A,  Tang P  S,  Chan W  C  W.   The effect of nanoparticlesize,  shape, and surface chemistry on biological systems[J].  AnnualReview ofBiomedicalEngineering, 2012, 14: 1-16.
[32] ReviaRA, Stephen Z R, ZhangM.  Theranosticnanoparticles forRNA-Based cancer treatment[J].   Accounts of Chemical Research, 2019, 52(6) : 1496-1506.
[33] CongYS, WrightW E, ShayJW.  Human telomeraseanditsregulation[J].  Microbiology and Molecular Biology Reviews, 2002, 66(3) : 407-425.
[34] Shay J W ,  Wright W  E.   Telomerase:  a target for cancer therapeutics[J].  CancerCell, 2002, 2(4) : 257-265.

备注/Memo

备注/Memo:
网络出版日期 : 2026-04-29收稿日期 : 2025-04-21基金项目 : 国家自然科学基金项目(32172496)作者简介 : 陆明冬(1998— ) ,男 ,安徽滁州人 ,硕士研究生 ,主要从事 RNA纳米表征及生物学功能方面的研究。通信作者: 金伟波,E-mail:jwb@zstu. edu. cn
更新日期/Last Update: 2026-09-21